Human leucocyte antigen‐C in B chronic lymphocytic leukaemia

Montes-Ares, Olga; Moya‐Quiles, María Rosa; Montes-Casado, María; Guerra-Pérez, Natalia; Campillo, José A.; Gonzalez, Celia; López-Bermejo, Antonio; Tamayo, Manuel; Majado, Maria Juliana; Parrado, Antonio; Muro, Manuel; Marı́n, Luis; Álvarez-López, María R.

doi:10.1111/j.1365-2141.2006.06334.x

Cited by 9 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study results of HLA class I alleles and CLL risk have been mixed. A small study of 98 patients in Spain reported the HLA‐Cw*16 allele to be associated with a 2.69 increased risk of developing CLL . Among CLL patients with a family history of CLL, the HLA‐DRB1*11 alleles were associated with increased CLL risk ( P ‐value = 0.009) .…”

Section: Chronic Lymphocytic Leukaemia/small Lymphocytic Lymphomamentioning

confidence: 99%

The role of HLA variation in lymphoma aetiology and survival

et al. 2019

View full text Add to dashboard Cite

Epidemiologic and laboratory evidence has consistently supported a strong inflammatory and immune component for lymphoma aetiology. These studies have consistently implicated variation in the immune gene, human leucocyte antigen (HLA), to be associated with lymphoma risk. In this review, we summarize the historical and recent evidence of HLA in both lymphoma aetiology and survival. The recent momentum in uncovering HLA associations has been propelled by the conduct of genome‐wide association studies (GWAS), which has permitted the evaluation of imputed HLA alleles in much larger sample sizes than historically feasible with allelotyping studies. Based on the culmination of smaller HLA typing studies and larger GWAS, we now recognize several HLA associations with Hodgkin (HL) and non‐Hodgkin lymphomas (NHLs) and their subtypes. Although other genetic variants have also been implicated with lymphoma risk, it is notable that HLA associations have been reported in every NHL and HL subtype evaluated to date. Both HLA class I and class II alleles have been linked with NHL and HL risk. It is notable that the associations identified are largely specific to each lymphoma subtype. However, pleiotropic HLA associations have also been observed. For example, rs10484561, which is in linkage disequilibrium with HLA‐DRB1*01:01˜DQA1*01:01˜DQB1*05:01, has been implicated in increased FL and DLBCL risk. Opposing HLA associations across subtypes have also been reported, such as for HLA‐A*01:01 which is associated with increased risk of EBV‐positive cHL but decreased risk of EBV‐negative cHL and chronic lymphocytic leukaemia/small cell lymphoma. Due to extensive linkage disequilibrium and allele/haplotypic variation across race/ethnicities, identification of causal alleles/haplotypes remains challenging. Follow‐up functional studies are needed to identify the specific immunological pathways responsible in the multifactorial aetiology of HL and NHL. Correlative studies linking HLA alleles with known molecular subtypes and HLA expression in the tumours are also needed. Finally, additional association studies investigating HLA diversity and lymphoma survival are also required to replicate initial associations reported to date.

show abstract

Section: Chronic Lymphocytic Leukaemia/small Lymphocytic Lymphomamentioning

confidence: 99%

The role of HLA variation in lymphoma aetiology and survival

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Apart of a few studies [4,16,[19][20][21][22][23][24][25][26] in which the frequency of HLA alleles has been determined in CLL patients from some ethnic populations, association of HLA alleles and CLL prognosis has not been well studied, especially in the Asian CLL patients. In a prior study we reported the frequency of some HLA class I A, B and C antigens in a limited number of CLL patients using the serological microlymphocytotoxicity technique [4].…”

Section: Introductionmentioning

confidence: 99%

Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

et al. 2014

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is a malignant disorder of B cell origin, with low incidence in Asian populations. In this study we investigated the HLA-class I A and B allele frequencies in 87 Iranian CLL patients and 64 healthy controls using sequence specific primer-polymerase chain reaction (SSP-PCR) technique. Our results showed increased frequencies of HLA-A11:01 (p=0.02) and HLA-B35:01 (p=0.002) alleles and HLA-A11:01/B35:01 haplotype (p=0.036) and decreased frequencies of HLA-A01:01 (p=0.02), HLA-A26:01 (p=0.03), HLA-B65:01 (p=0.03) and HLA-B53:01 (p<0.00001) alleles in CLL patients compared to the control group.Classification of the patients into non-progressive and progressive groups did not reveal significant differences for the frequency of any of the HLA-A and B alleles or haplotypes between these two subtypes. Comparison between patients with immunoglobulin heavy chain variable region genes (IGHV) mutated (n=56) and unmutated (n=31) subtypes showed a significant increase in HLA-A32:01 (p=0.05) and HLA-A33:01 (p=0.05) alleles in IGHV unmutated patients compared to IGHV mutated patients. Similarly, a higher frequency of HLA-B52:01 (p=0.037) alleles was observed in CD38+ compared with CD38-patients. Our results obtained from an Iranian population indicate that CLL is associated with distinct HLA class I alleles and haplotypes some of which are linked to disease prognostic factors.3

show abstract

“…Previous studies have shown a relationship between HLA polymorphisms and susceptibility to certain hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute lymphoblastic leukemia. [9][10][11] However, there is little information about the relationship between HLA polymorphisms and susceptibility to developing B-NHL or their outcomes. [12][13][14][15][16] Focusing on diffuse large B-cell lymphoma (DLBCL), some associations between HLA specificities and this B-NHL subtype have been described, as well as with other genetic polymorphisms.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, we describe for the first time the role of HLA polymorphisms in the prognosis of DLBCL patients receiving rituximabbased regimens as first-line treatment. Our results show that the presence of the HLA-DRB1*01 and the absence of HLA-C*03 polymorphism are associated with susceptibility to DLBCL, while the HLA-B44 supertype, especially the presence of HLA-B*18 and HLA-B*44 polymorphisms, have an independent influence on survival.The HLA system has been related to susceptibility to several hematologic and nonhematologic diseases, [9][10][11]36 including a variety of HLA polymorphisms associated with B-NHL development and outcome. [12][13][14][15][16] However, this feature has not been extensively studied specifically in DLBCL, although some data suggest an association between HLA subtypes and disease susceptibility (ie, a higher incidence of HLA-DRB1*04:01 allele in this lymphoma subgroup).…”

mentioning

confidence: 99%

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Alcoceba

Sebastián

Marı́n

et al. 2013

Blood

Self Cite

View full text Add to dashboard Cite

Key Points• DLBCL patients carrying the HLA-B44 supertype have a worse progression-free and overall survival after R-CHOP-like treatment.• The HLA-DRB1*01 allele increases the risk of DLBCL development.Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease influenced by genetic and environmental factors. The role of the HLA system in tumor antigen presentation could be involved in susceptibility and disease control. We analyzed the phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 in 250 DLBCLs, comparing them with 1940 healthy individuals. We also evaluated the influence of HLA polymorphisms on survival in those patients treated with curative intention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n 5 64, 26%) or with (n 5 153, 61%) rituximab. DLBCL patients have a higher phenotypic frequency of HLA-DRB1*01 (29% vs 19.5%, P 5 .0008, Pc 5 .0104) and a lower frequency of HLA-C*03 (6.4% vs 17.9%, P < .0005, Pc 5 .007) compared with healthy individuals. Irrespective of the age-adjusted International Prognostic Index, those patients receiving a CHOP-like plus rituximab regimen and carrying the HLA-B44 supertype had worse 5-year progression-free (54% vs 71%, P 5 .019) and 5-year overall (71% vs 92%, P 5 .001) survival compared with patients without this supertype. Our data suggest that some HLA polymorphisms influence the development and outcome of DLBCL, allowing the identification of an extremely good-risk prognostic subgroup. However, these results are preliminary and need to be validated in order to exclude a possible population effect. (Blood. 2013;122(8):1448-1454 IntroductionSeveral genetic polymorphisms have been associated with susceptibility or prognosis in various B-cell non-Hodgkin lymphoma (B-NHL) subtypes.1,2 In recent years, genome-wide association studies have identified 6p21.3 as a risk region for susceptibility of different lymphomas, such as follicular lymphoma [3][4][5] or Hodgkin lymphoma. 6,7 The HLA system, located in this region, plays a key role in antitumor immune responses and lymphoma-cell apoptosis 8 and so may be essential for neoplasia control. Previous studies have shown a relationship between HLA polymorphisms and susceptibility to certain hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute lymphoblastic leukemia.9-11 However, there is little information about the relationship between HLA polymorphisms and susceptibility to developing B-NHL or their outcomes.12-16 Focusing on diffuse large B-cell lymphoma (DLBCL), some associations between HLA specificities and this B-NHL subtype have been described, as well as with other genetic polymorphisms. Shorter progression-free survival (PFS) and overall survival (OS) have been observed in DLBCL patients lacking the HLA-DR2 or carrying TNF -308A.13 In addition, OS is shorter in those patients carrying the C*07-B*08-LTA1 252G -TNF -308A haplotype 14 or the HLA-C*07:01. 16 However, these studies considered patients treated before...

show abstract

Human leucocyte antigen‐C in B chronic lymphocytic leukaemia

Cited by 9 publications

References 11 publications

The role of HLA variation in lymphoma aetiology and survival

The role of HLA variation in lymphoma aetiology and survival

Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Contact Info

Product

Resources

About